These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24945562)

  • 1. Genotype characterization of occult hepatitis B virus strains among Egyptian chronic hepatitis C patients.
    Kishk R; Atta HA; Ragheb M; Kamel M; Metwally L; Nemr N
    East Mediterr Health J; 2014 Mar; 20(2):130-8. PubMed ID: 24945562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
    J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
    Levast M; Larrat S; Thelu MA; Nicod S; Plages A; Cheveau A; Zarski JP; Seigneurin JM; Morand P; Leroy V
    J Med Virol; 2010 May; 82(5):747-54. PubMed ID: 20336715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
    Coppola N; Pisapia R; Tonziello G; Martini S; Imparato M; Piai G; Stanzione M; Sagnelli C; Filippini P; Piccinino F; Sagnelli E
    Antivir Ther; 2008; 13(2):307-18. PubMed ID: 18505182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.
    Emara MH; El-Gammal NE; Mohamed LA; Bahgat MM
    Virol J; 2010 Nov; 7():324. PubMed ID: 21083926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
    Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
    Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
    Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
    Saitta C; Pontisso P; Brunetto MR; Fargion S; Gaeta GB; Niro GA; Picciotto A; Smedile A; Squadrito G; Raimondo G
    Antivir Ther; 2006; 11(7):931-4. PubMed ID: 17302256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
    Fabris P; Brown D; Tositti G; Bozzola L; Giordani MT; Bevilacqua P; de Lalla F; Webster GJ; Dusheiko G
    J Clin Virol; 2004 Mar; 29(3):160-6. PubMed ID: 14962784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance.
    Cardoso C; Alves AL; Augusto F; Freire R; Quintana C; Gonçalves M; Oliveira AP
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):142-6. PubMed ID: 23044809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
    Yu JW; Sun LJ; Zhao YH; Kang P; Gao J; Li SC
    Liver Int; 2009 Nov; 29(10):1485-93. PubMed ID: 19602134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Yu ML; Lee CM; Chuang WL; Lu SN; Dai CY; Huang JF; Lin ZY; Hu TH; Chen CH; Hung CH; Wang JH; Chen CL; Kao JH; Lai MY; Liu CH; Su TH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Chen PJ; Liu CJ; Chen DS
    J Infect Dis; 2010 Jul; 202(1):86-92. PubMed ID: 20482252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
    Cacciola I; Pollicino T; Squadrito G; Cerenzia G; Orlando ME; Raimondo G
    N Engl J Med; 1999 Jul; 341(1):22-6. PubMed ID: 10387938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
    Mrani S; Chemin I; Menouar K; Guillaud O; Pradat P; Borghi G; Trabaud MA; Chevallier P; Chevallier M; Zoulim F; Trépo C
    J Med Virol; 2007 Aug; 79(8):1075-81. PubMed ID: 17596829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.